Total Lymphoid Irradiation–Antithymocyte Globulin Conditioning and Allogeneic Transplantation for Patients with Myelodysplastic Syndromes and Myeloproliferative Neoplasms

Fenaux, 2009, Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study, Lancet Oncol, 10, 223, 10.1016/S1470-2045(09)70003-8 Itzykson, 2011, Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine, Blood, 117, 403, 10.1182/blood-2010-06-289280 Cutler, 2004, A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome, Blood, 104, 579, 10.1182/blood-2004-01-0338 Koreth, 2013, Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis, J Clin Oncol, 31, 2662, 10.1200/JCO.2012.46.8652 McClune, 2010, Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome, J Clin Oncol, 28, 1878, 10.1200/JCO.2009.25.4821 Scott, 2006, Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis, Leukemia, 20, 128, 10.1038/sj.leu.2404010 Alyea, 2006, Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome, Biol Blood Marrow Transplant, 12, 1047, 10.1016/j.bbmt.2006.06.003 Kohrt, 2009, TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors, Blood, 114, 1099, 10.1182/blood-2009-03-211441 Messina, 2012, Multicenter experience using total lymphoid irradiation and antithymocyte globulin as conditioning for allografting in hematological malignancies, Biol Blood Marrow Transplant, 18, 1600, 10.1016/j.bbmt.2012.03.012 Lowsky, 2005, Protective conditioning for acute graft-versus-host disease, New Engl J Med, 353, 1321, 10.1056/NEJMoa050642 Arai, 2012, Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence, Blood, 119, 6145, 10.1182/blood-2011-12-395970 Pillai, 2009, Host natural killer T cells induce an interleukin-4-dependent expansion of donor CD4+CD25+Foxp3+ T regulatory cells that protects against graft-versus-host disease, Blood, 113, 4458, 10.1182/blood-2008-06-165506 Greenberg, 2012, Revised international prognostic scoring system for myelodysplastic syndromes, Blood, 120, 2454, 10.1182/blood-2012-03-420489 Sorror, 2007, Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation, J Clin Oncol, 25, 4246, 10.1200/JCO.2006.09.7865 Millan, 2002, Mixed chimerism and immunosuppressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitor transplantation, Transplantation, 73, 1386, 10.1097/00007890-200205150-00005 Baron, 2006, Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning, Leukemia, 20, 1690, 10.1038/sj.leu.2404335 Przepiorka, 1995, 1994 Consensus Conference on Acute GVHD Grading, Bone Marrow Transplant, 15, 825 Filipovich, 2005, National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. diagnosis and staging working group report, Biol Blood Marrow Transplant, 11, 945, 10.1016/j.bbmt.2005.09.004 Kaplan, 1958, Nonparametric estimation from incomplete observations, J Am Stat Assoc, 53, 457, 10.1080/01621459.1958.10501452 Gooley, 1999, Estimation of failure probabilities in the presence of competing risks: new representations of old estimators, Stat Med, 18, 695, 10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O Laport, 2011, Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation, Biol Blood Marrow Transplant, 17, 1679, 10.1016/j.bbmt.2011.05.012 Scott, 2006, Hemopoietic cell transplantation as curative therapy of myelodysplastic syndromes and myeloproliferative disorders, Best Pract Res Clin Haematol, 19, 519, 10.1016/j.beha.2005.07.009 Laport, 2008, Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders, Biol Blood Marrow Transplant, 14, 246, 10.1016/j.bbmt.2007.11.012 Nakamura, 2007, Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome, Bone Marrow Transplant, 40, 843, 10.1038/sj.bmt.1705801 Potter, 2014, Long-term outcomes of alemtuzumab-based reduced-intensity conditioned hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myelogenous leukemia secondary to myelodysplastic syndrome, Biol Blood Marrow Transplant, 20, 111, 10.1016/j.bbmt.2013.10.021 Martino, 2006, Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes, Blood, 108, 836, 10.1182/blood-2005-11-4503 Luger, 2011, Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS, Bone Marrow Transplant Lim, 2010, Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia, J Clin Oncol, 28, 405, 10.1200/JCO.2009.21.8073 Bacigalupo, 2001, Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO), Blood, 98, 2942, 10.1182/blood.V98.10.2942 Finke, 2009, Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial, Lancet Oncol, 10, 855, 10.1016/S1470-2045(09)70225-6 Soiffer, 2011, Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies, Blood, 117, 6963, 10.1182/blood-2011-01-332007 Pillai, 2007, Host NKT cells can prevent graft-versus-host disease and permit graft antitumor activity after bone marrow transplantation, J Immunol, 178, 6242, 10.4049/jimmunol.178.10.6242 Childs, 1999, Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses, Blood, 94, 3234, 10.1182/blood.V94.9.3234 Baron, 2004, Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning, Blood, 104, 2254, 10.1182/blood-2004-04-1506 Flowers, 2011, Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria, Blood, 117, 3214, 10.1182/blood-2010-08-302109 Cutler, 2007, Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation, Blood, 109, 3108, 10.1182/blood-2006-09-046219 Ringden, 2011, Sirolimus and tacrolimus as immune prophylaxis compared to cyclosporine with or without methotrexate in patients undergoing allogeneic haematopoietic stem cell transplantation for non-malignant disorders, Eur J Haematol, 87, 503, 10.1111/j.1600-0609.2011.01685.x Malcovati, 2007, Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes, J Clin Oncol, 25, 3503, 10.1200/JCO.2006.08.5696 Silverman, 2006, Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B, J Clin Oncol, 24, 3895, 10.1200/JCO.2005.05.4346 Prebet, 2013, Outcome of patients with low risk myelodysplasia after azacitidine treatment failure, Haematologica, 98, e18, 10.3324/haematol.2012.071050 Jabbour, 2010, Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy, Cancer, 116, 3830, 10.1002/cncr.25247 Prebet, 2011, Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure, J Clin Oncol, 29, 3322, 10.1200/JCO.2011.35.8135